# Alderaan Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alderaan-biotechnology

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.alderaan-biotechnology.com
- Total disclosed funding: $28M
- Latest round: Series A (Mar 31, 2022)
- Investors on record: 2

## About

Based in Paris, France, and founded in 2017 by its CEO, Dr. Arnaud Foussat, and co-founders Armand Bensussa, and Daniel Olive, Alderaan Biotechnology operates as a company dedicated to the development of therapies for cancer treatment, with a specific focus on modulating immune cells. In January 2020, Alderaan Biotechnology raised EUR 18.5 million in Series A funding led by Advent France Biotechnology (AFB) with participation from Medicxi.  

Alderaan Biotechnology developed CD25-specific monoclonal antibodies that deplete Treg cells from the tumor microenvironment while sparing effector T cells responsible for tumor destruction. Additionally, the company develops antibodies that target CD160-TM to enhance the cytotoxic activity of NK cells, leading to increased cancer cell destruction within the tumor and triggering an immune response against the tumor.

## Funding rounds

- Series A, Mar 31, 2022, $3.9M — Medicxi, AdBio Partners
- Series A, Jan 20, 2021, $2.4M — Medicxi, AdBio Partners
- Series A, Jan 9, 2020, $21M — Medicxi, AdBio Partners
- Series A, Feb 15, 2018, $1.2M — AdBio Partners

## Investors

- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Series A
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series A